GLP-1 & Incretin Science

The Survodutide Comparison, Read Properly

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Blüher and colleagues compared survodutide against placebo and an open-label semaglutide arm in adults with type 2 diabetes, published in Diabetologia in 2024. The semaglutide arm was open-label and the trial was dose-finding, which makes this weaker evidence than a blinded head-to-head.

Key facts

Compound
Survodutide (BI 456906)
Class
GLP-1 / glucagon dual agonist
Comparators
Placebo and open-label semaglutide
Population
Adults with type 2 diabetes
Published
Diabetologia 2024 (PMID 38095657)
Correction issued
Diabetologia 2024 (PMID 38349400)
Design
Dose-response, not a pivotal head-to-head

What the trial was for

Dose-response. Its primary purpose was establishing how HbA1c and body weight reduction varied across survodutide doses, a dose-finding exercise. The semaglutide arm was included as a reference point, not as the trial's reason for existing.

Why open-label matters

Participants and investigators knew who was receiving semaglutide. Blinding exists because knowledge of assignment influences reported outcomes, adherence and adverse event reporting. An open-label comparator arm is informative context; it is not the same evidential object as a double-blind randomised comparison, and results from it should carry that qualification.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The confusion in circulation

Figures from this trial are routinely mixed with figures from a separate 46-week trial in participants with overweight or obesity without diabetes. Those are different populations, different durations and different endpoints. A number quoted without its population and duration attached cannot be checked, and in this compound's coverage that happens constantly.

Why a correction was published

Diabetologia issued a correction to the paper in 2024. Corrections are routine and usually minor, but they are part of the published record and citing the original without checking whether one exists is how errors persist. This site's citation checking now surfaces them.

What the glucagon component contributes

Survodutide adds glucagon receptor agonism to GLP-1 activity, which raises energy expenditure and mobilises hepatic fat. It is the same rationale behind retatrutide's third receptor, and it is why compounds in this class are also studied in metabolic liver disease rather than weight alone.

What it is not

Survodutide is investigational. Semaglutide is a licensed medicine. Neither is related to research material, and comparing their trial results has no bearing on anything supplied here.

Frequently asked questions

Why do quoted survodutide numbers vary so much?

Figures from this type 2 diabetes trial are frequently mixed with those from a separate 46-week trial in a different population without diabetes.

What does the glucagon receptor add?

Increased energy expenditure and mobilisation of hepatic fat, the same rationale as retatrutide's third receptor.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.